Oramed Pharmaceuticals Inc (ORMP)
2.42
-0.07
(-2.81%)
USD |
NASDAQ |
May 07, 12:21
Oramed Pharmaceuticals Research and Development Expense (Quarterly): 1.766M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.766M |
| September 30, 2023 | 0.957M |
| June 30, 2023 | 1.821M |
| March 31, 2023 | 4.427M |
| December 31, 2022 | 7.277M |
| September 30, 2022 | 5.347M |
| June 30, 2022 | 9.179M |
| March 31, 2022 | 5.836M |
| November 30, 2021 | 6.41M |
| August 31, 2021 | 5.844M |
| May 31, 2021 | 5.502M |
| February 28, 2021 | 3.869M |
| November 30, 2020 | 5.774M |
| August 31, 2020 | 2.968M |
| May 31, 2020 | 1.925M |
| February 29, 2020 | 3.32M |
| November 30, 2019 | 2.022M |
| August 31, 2019 | 2.20M |
| May 31, 2019 | 3.861M |
| February 28, 2019 | 3.114M |
| November 30, 2018 | 4.347M |
| August 31, 2018 | 2.734M |
| May 31, 2018 | 4.194M |
| February 28, 2018 | 2.724M |
| November 30, 2017 | 2.327M |
| Date | Value |
|---|---|
| August 31, 2017 | 2.536M |
| May 31, 2017 | 2.267M |
| February 28, 2017 | 3.125M |
| November 30, 2016 | 2.353M |
| August 31, 2016 | 2.795M |
| May 31, 2016 | 1.71M |
| February 29, 2016 | 1.303M |
| November 30, 2015 | 1.901M |
| August 31, 2015 | 1.428M |
| May 31, 2015 | 0.915M |
| February 28, 2015 | 1.136M |
| November 30, 2014 | 1.302M |
| August 31, 2014 | 0.764M |
| May 31, 2014 | 1.089M |
| February 28, 2014 | 0.674M |
| November 30, 2013 | 0.75M |
| August 31, 2013 | 0.2947M |
| May 31, 2013 | 0.8356M |
| February 28, 2013 | 0.749M |
| November 30, 2012 | 0.3926M |
| August 31, 2012 | 0.5366M |
| May 31, 2012 | 0.2498M |
| February 29, 2012 | 0.7106M |
| November 30, 2011 | 0.184M |
| August 31, 2011 | 0.2901M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.957M
Minimum
Sep 2023
9.179M
Maximum
Jun 2022
4.227M
Average
3.869M
Median
Feb 2021
Research and Development Expense (Quarterly) Benchmarks
| Inogen Inc | 6.714M |
| Petros Pharmaceuticals Inc | 0.8343M |
| DIH Holding US Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |